A rare case of fatal hepatic veno-occlusive disease and rupture of the spleen vein and artery after Gemtuzumab Ozogamicin (Mylotarg®) infusion Doença veno-oclusiva fatal por Gentuzumab Ozogamicin

Autor:	Celso M. Massumoto, Ronald F. Pinheiro, Edilson D. Pinheiro Júnior, Otávio C. Baiocchi, Adelson Alves
Jazyk:	angličtina
Rok vydání:	2004
Předmět:	Gentuzumab Ozogamicina doença hepática veno-oclusiva vasos hepáticos Gemtuzumab Ozogamicin Hepatic veno-occlusive disease spleen vases Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Revista Brasileira de Hematologia e Hemoterapia, Vol 26, Iss 3, Pp 218-220 (2004)
Druh dokumentu:	article
ISSN:	1516-8484 1806-0870
DOI:	10.1590/S1516-84842004000300013
Popis:	Gemtuzumab Ozogamicin (Mylotarg®) targets leukemia cells expressing the CD 33 receptor by means of a monoclonal antibody conjugated to a cytotoxic agent, calicheamicin. It was approved for use in elderly patients with relapsed or refractory acute myeloid leukemia and reversible hepatotoxicity is common after administration. The first case of hepatic veno-occlusive disease was reported after Gemtuzumab Ozogamicin infusion in a patient who had been submitted to hematopoietic stem cell transplantation 8 months earlier. Three phase 2 studies with 188 patients with acute myeloid leukemia in first relapse that used Gemtuzumab Ozogamicin were analysed and the incidence of fatal hepatic veno-occlusive disease in these studies was < 1%, and prior hematopoietic stem cell transplantation was the most significant risk factor. The aim of this paper is to report a rare fatal case of hepatic veno-occlusive disease with rupture of the spleen vein and artery in a 68-year-old patient that had received Gemtuzumab Ozogamicin. To the best of our knowledge, it is the first case report of hepatic veno-occlusive disease with rupture of the spleen vein and artery related to Gemtuzumab Ozogamicin.Gentuzumab Ozogamicina (GO) (Mylotarg®) tem como alvo células leucêmicas que expressam CD33 através de um anticorpo monoclonal conjugado a um agente citotóxico, a caliqueamicina. Esta droga foi aprovada para uso em pacientes idosos com leucemia mielóide aguda (LMA) recaída ou refratária e hepatotoxicidade é comum após sua administração. Tack e colaboradores apresentaram o primeiro caso de doença hepática veno-oclusiva (DHVO) após infusão de GO em um paciente que tinha realizado transplante de medula( TMO) há 8 meses. Três estudos de fase II com 188 pacientes com LMA foram analisados e a incidência de HVOD fatal foi inferior a 1%, sendo a realização de TMO o fator de risco mais importante. O objetivo deste artigo é relatar um caso raro de DHVO fatal com ruptura de veia e artéria hepática em um paciente de 68 anos que recebeu GO. Acreditamos que este é o primeiro relato de HVOD com ruptura de vasos hepáticos relacionado ao uso de GO.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/ec015a5289c9438e9fd43dec63587050 Zobrazit plný text záznamu View record in DOAJ